Table 3

Univariate analysis of factors associated IC versus no IC

ICNo ICP value
Total N6790
Age (years), median (IQR)54 (50–57)55 (53–58)0.45
Sex (male)48 (72%)33 (37%)0.63
Stem cell transplant16 (24%)18 (20%)0.56
Hematologic malignancy32 (48%)48 (53%)0.52
Abdominal malignancy21 (31%)32 (36%)0.61
Chemo<6 weeks33 (49%)57 (63%)0.10
Abdominal radiation2 (3.0%)7 (7.8%)0.30
Steroids8 (12%)17 (19%)0.28
Nausea/vomiting41 (61%)41 (46%)0.06
ANC (1000 cells/μL), median (IQR)6.4 (5.0–7.7)5.3 (3.8–6.9)0.36
Platelets (1000/μL), median (IQR)171 (144–198)130 (108–152)0.02
Length of stay (days), median (IQR)6 (3–9)6 (3–12)0.41
ASA
 I0 (0%)0 (0%)0.58
 II7 (12%)7 (7.8%)
 III48 (80%)84 (93%)
 IV19 (32%)40 (44%)
 V0 (0%)1 (1.1%)
  • Chemo<6 weeks indicates chemotherapy received less than 6 weeks to presentation.

  • ANC, absolute neutrophil count; ASA, American Society of Anesthesiologists; IC, interval cholecystectomy; PCT, percutaneous cholecystostomy tube.